Cash Injection Fuels Viela Bio's NMOSD FDA Filing
Executive Summary
New and existing investors in Viela Bio have raised $75m in the latest funding round, allowing the AstraZeneca spin off to progress its NMOSD antibody to regulatory filing in the US. However, established companies may have stolen a march on commercializing a treatment.
You may also be interested in...
Finance Watch: Summer Slowdown Nears Its End With Strategic Shifts And IPO Hopes
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
Rivals Await CHMP Decisions On Drugs For NMOSD
The European Medicines Agency’s drug evaluation committee, the CHMP, is this week considering products from Alexion Pharmaceuticals and Roche/Chugai Pharmaceutical who are both vying for a share of the as yet untapped EU market for neuromyelitis optica spectrum disorder.
Chugai May Not Win Race For $500m Neuromyelitis Optica Market, But May Best Soliris On Ease Of Use
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.